AP2005003341A0 - 2-(1H-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatmentof ophthalmic diseases - Google Patents

2-(1H-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatmentof ophthalmic diseases

Info

Publication number: AP2005003341A0
Authority: AP; ARIPO
Prior art keywords: treatmentof; ylamino; indazole; protein kinases; inhibitors useful
Prior art date: 2002-12-19

Application number

AP2005003341A

Other languages

English (en)

Inventor

Allen J Borchardt

Robert Steven Kania

Cynhia Louise Palmer

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-19

Filing date

2003-12-08

Publication date

2005-06-30

2003-12-08 Application filed by Pfizer filed Critical Pfizer

2005-06-30 Publication of AP2005003341A0 publication Critical patent/AP2005003341A0/xx

Links

CVFYRHWYZPZVTJ-UHFFFAOYSA-N 2-(1h-indazol-6-ylamino)benzamide Chemical class NC(=O)C1=CC=CC=C1NC1=CC=C(C=NN2)C2=C1 CVFYRHWYZPZVTJ-UHFFFAOYSA-N 0.000 title 1
102000001253 Protein Kinase Human genes 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
108060006633 protein kinase Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AP2005003341A 2002-12-19 2003-12-08 2-(1H-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatmentof ophthalmic diseases AP2005003341A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43490202P	2002-12-19	2002-12-19
PCT/IB2003/005854 WO2004056806A1 (en)	2002-12-19	2003-12-08	2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases

Publications (1)

Publication Number	Publication Date
AP2005003341A0 true AP2005003341A0 (en)	2005-06-30

Family

ID=32682122

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2005003341A AP2005003341A0 (en)	2002-12-19	2003-12-08	2-(1H-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatmentof ophthalmic diseases

Country Status (37)

Country	Link
US (2)	US7053107B2 (pl)
EP (1)	EP1585743B1 (pl)
JP (1)	JP3814285B2 (pl)
KR (1)	KR100730267B1 (pl)
CN (1)	CN1747950A (pl)
AP (1)	AP2005003341A0 (pl)
AR (1)	AR042510A1 (pl)
AT (1)	ATE362928T1 (pl)
AU (1)	AU2003286321A1 (pl)
BR (1)	BR0317548A (pl)
CA (1)	CA2510850A1 (pl)
CO (1)	CO5580767A2 (pl)
CR (1)	CR7882A (pl)
DE (1)	DE60314013T2 (pl)
DK (1)	DK1585743T3 (pl)
EA (1)	EA008501B1 (pl)
EC (1)	ECSP055858A (pl)
GT (1)	GT200300294A (pl)
HR (1)	HRP20050559A2 (pl)
IS (1)	IS7859A (pl)
MA (1)	MA27570A1 (pl)
MX (1)	MXPA05006676A (pl)
NL (1)	NL1025073C2 (pl)
NO (1)	NO20053486L (pl)
NZ (1)	NZ540340A (pl)
OA (1)	OA12977A (pl)
PA (1)	PA8592901A1 (pl)
PE (1)	PE20041006A1 (pl)
PL (1)	PL377713A1 (pl)
PT (1)	PT1585743E (pl)
RS (1)	RS20050430A (pl)
SI (1)	SI1585743T1 (pl)
TN (1)	TNSN05164A1 (pl)
TW (1)	TW200424193A (pl)
UY (1)	UY28130A1 (pl)
WO (1)	WO2004056806A1 (pl)
ZA (1)	ZA200504339B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA89035C2 (ru)	2003-12-03	2009-12-25	Лео Фарма А/С	Эфиры гидроксамовых кислот и их фармацевтическое применение
WO2005094823A1 (ja) *	2004-03-30	2005-10-13	Kyowa Hakko Kogyo Co., Ltd.	Ｆｌｔ－３阻害剤
US20060182783A1 (en) *	2004-04-30	2006-08-17	Allergan, Inc.	Sustained release intraocular drug delivery systems
WO2006043172A1 (en) *	2004-10-19	2006-04-27	Pfizer Inc.	Pharmaceutical compositions and methods for sub-tenon delivery
AU2005300311A1 (en) *	2004-11-02	2006-05-11	Pfizer Inc.	Methods for preparing indazole compounds
US20060160863A1 (en) *	2005-01-05	2006-07-20	Agouron Pharmaceuticals, Inc.	Polymorphic and amorphous forms of 2-{3-[(E)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1H-indazol-6-ylamino}-N-(4-hydroxy-but-2-ynyl)benzamide
WO2006117666A2 (en) *	2005-04-29	2006-11-09	Pfizer Inc.	Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
US8297028B2 (en)	2006-06-14	2012-10-30	The Invention Science Fund I, Llc	Individualized pharmaceutical selection and packaging
US10296720B2 (en)	2005-11-30	2019-05-21	Gearbox Llc	Computational systems and methods related to nutraceuticals
US7827042B2 (en)	2005-11-30	2010-11-02	The Invention Science Fund I, Inc	Methods and systems related to transmission of nutraceutical associated information
US7974856B2 (en)	2005-11-30	2011-07-05	The Invention Science Fund I, Llc	Computational systems and methods related to nutraceuticals
US7927787B2 (en)	2006-06-28	2011-04-19	The Invention Science Fund I, Llc	Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en)	2005-11-30	2012-12-25	The Invention Science Fund I, Llc	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20080103746A1 (en) *	2005-11-30	2008-05-01	Searete Llc, A Limited Liability Corporation	Systems and methods for pathogen detection and response
US8000981B2 (en)	2005-11-30	2011-08-16	The Invention Science Fund I, Llc	Methods and systems related to receiving nutraceutical associated information
US20100048660A1 (en) *	2006-02-10	2010-02-25	Graham Michael Wynne	Treatment of duchenne muscular dystrophy
JPWO2008020606A1 (ja) *	2006-08-16	2010-01-07	協和発酵キリン株式会社	血管新生阻害剤
JP2010524864A (ja) *	2007-04-19	2010-07-22	レオファーマアクティーゼルスカブ	Ｓｒｃファミリーキナーゼ阻害剤
BRPI0810063A2 (pt)	2007-04-20	2014-10-14	Acucela Inc	Composto, composição farmacêutica, e, métodos para modular fluxo de cromóforo em um ciclo retinóide, para tratar uma doença ou distúrbio oftálmico em um indivíduo, para inibir adaptação ao escuro em uma célula fotorreceptora de bastão da retina, para inibir regeneração de rodopsina em uma célula fotoreceptora de bastão da retina, para reduzir isquemia em um olho de um indivíduo, para inibir neovascularização na retina de um olho de um indivíduo, e para inibir degeneração de uma célula da retina em uma retina
US20090081277A1 (en) *	2007-09-21	2009-03-26	Allergan, Inc.	Pharmaceutical formulations and methods for treating ocular conditions
EP2346827B1 (en)	2008-08-27	2013-11-13	Leo Pharma A/S	Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors
HRP20160967T1 (hr) *	2009-10-06	2016-10-07	Millennium Pharmaceuticals, Inc.	Heterociklički spojevi korisni kao pdk1 inhibitori
CN103804349A (zh) *	2012-11-01	2014-05-21	杨子娇	一类治疗青光眼的化合物及其用途
JO3425B1 (ar)	2013-07-15	2019-10-20	Novartis Ag	مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
WO2015152117A1 (ja) *	2014-03-31	2015-10-08	千寿製薬株式会社	アルキニルインダゾール誘導体及びその用途
CN104744338A (zh) *	2015-03-31	2015-07-01	天津维智精细化工有限公司	一种6-氯羟吲哚的合成方法
EP3333157B1 (en) *	2015-08-07	2020-12-23	Harbin Zhenbao Pharmaceutical Co., Ltd.	Vinyl compounds as fgfr and vegfr inhibitors
CN109942544B (zh) *	2017-12-21	2021-06-11	中国科学院合肥物质科学研究院	一类新型吲唑类衍生物激酶抑制剂
WO2024032584A1 (zh) *	2022-08-08	2024-02-15	苏州必扬医药科技有限公司	一种蛋白酪氨酸激酶抑制剂及其医疗用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
FI941572L (fi) *	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) *	1992-02-06	1997-02-27	Curis, Inc.	Biosynthetic binding protein for cancer marker
US5178635A (en) *	1992-05-04	1993-01-12	Allergan, Inc.	Method for determining amount of medication in an implantable device
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5443505A (en) *	1993-11-15	1995-08-22	Oculex Pharmaceuticals, Inc.	Biocompatible ocular implants
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1996014843A2 (en)	1994-11-10	1996-05-23	Cor Therapeutics, Inc.	Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
US5863949A (en) *	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) *	1995-04-20	2001-04-23	Pfizer	Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5773019A (en) *	1995-09-27	1998-06-30	The University Of Kentucky Research Foundation	Implantable controlled release device to deliver drugs directly to an internal portion of the body
GB9520822D0 (en)	1995-10-11	1995-12-13	Wellcome Found	Therapeutically active compounds
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
DE69624081T2 (de)	1995-12-20	2003-06-12	Agouron Pharmaceuticals, Inc.	Matrix-metalloprotease Inhibitoren
US6291455B1 (en)	1996-03-05	2001-09-18	Zeneca Limited	4-anilinoquinazoline derivatives
EP0888310B1 (en)	1996-03-15	2005-09-07	AstraZeneca AB	Cinnoline derivatives and use as medicine
US6071935A (en) *	1996-06-27	2000-06-06	Pfizer Inc.	Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
EP0818442A3 (en)	1996-07-12	1998-12-30	Pfizer Inc.	Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
ES2191187T3 (es)	1996-07-13	2003-09-01	Glaxo Group Ltd	Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
ID19609A (id)	1996-07-13	1998-07-23	Glaxo Group Ltd	Senyawa-senyawa heterosiklik
EP0923585B1 (en)	1996-07-18	2002-05-08	Pfizer Inc.	Phosphinate based inhibitors of matrix metalloproteases
WO1998007697A1 (en)	1996-08-23	1998-02-26	Pfizer Inc.	Arylsulfonylamino hydroxamic acid derivatives
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
WO1998030566A1 (en)	1997-01-06	1998-07-16	Pfizer Inc.	Cyclic sulfone derivatives
EP0977733B1 (en)	1997-02-03	2003-09-03	Pfizer Products Inc.	Arylsulfonylamino hydroxamic acid derivatives
JP2000507975A (ja)	1997-02-07	2000-06-27	ファイザー・インク	Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EA002546B1 (ru)	1997-02-11	2002-06-27	Пфайзер Инк.	Производные арилсульфонилгидроксамовой кислоты
EP0984930B1 (en)	1997-05-07	2005-04-06	Sugen, Inc.	2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en)	1997-05-30	1998-12-03	Merck & Co., Inc.	Novel angiogenesis inhibitors
US6658447B2 (en) *	1997-07-08	2003-12-02	Intel Corporation	Priority based simultaneous multi-threading
AU730248B2 (en)	1997-08-08	2001-03-01	Pfizer Products Inc.	Aryloxyarylsulfonylamino hydroxamic acid derivatives
WO1999010349A1 (en)	1997-08-22	1999-03-04	Zeneca Limited	Oxindolylquinazoline derivatives as angiogenesis inhibitors
WO1999016755A1 (en)	1997-09-26	1999-04-08	Merck & Co., Inc.	Novel angiogenesis inhibitors
CA2309690A1 (en)	1997-11-11	1999-05-20	Pfizer Products Inc.	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
JPH11236333A (ja) *	1997-12-30	1999-08-31	Pfizer Prod Inc	抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
RS49779B (sr)	1998-01-12	2008-06-05	Glaxo Group Limited,	Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
EA005032B1 (ru)	1998-05-29	2004-10-28	Сьюджен, Инк.	Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
UA60365C2 (uk)	1998-06-04	2003-10-15	Пфайзер Продактс Інк.	Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
DE69923849T2 (de)	1998-08-27	2006-01-12	Pfizer Products Inc., Groton	Quinolin-2-on-derivate verwendbar als antikrebsmittel
TR200101343T2 (tr) *	1998-08-27	2001-09-21	Pfizer Products Inc.	Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
DK1004578T3 (da)	1998-11-05	2004-06-28	Pfizer Prod Inc	5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
EP1006113A1 (en) *	1998-12-02	2000-06-07	Pfizer Products Inc.	Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
US6649645B1 (en)	1998-12-23	2003-11-18	Pharmacia Corporation	Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6682736B1 (en) *	1998-12-23	2004-01-27	Abgenix, Inc.	Human monoclonal antibodies to CTLA-4
BR9916536A (pt)	1998-12-23	2002-01-02	Searle & Co	Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
JP3270834B2 (ja) *	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) *	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
SK11002001A3 (sk) *	1999-02-11	2002-05-09	Pfizer Products Inc.	Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
US6586447B1 (en)	1999-04-01	2003-07-01	Pfizer Inc	3,3-disubstituted-oxindole derivatives useful as anticancer agents
US6511993B1 (en) *	1999-06-03	2003-01-28	Kevin Neil Dack	Metalloprotease inhibitors
TWI262914B (en) *	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) *	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EP1081137A1 (en)	1999-08-12	2001-03-07	Pfizer Products Inc.	Selective inhibitors of aggrecanase in osteoarthritis treatment
JP2001121829A (ja) *	1999-10-26	2001-05-08	Sony Chem Corp	情報記録用シート
PT1106612E (pt)	1999-11-30	2004-06-30	Pfizer Prod Inc	Derivados de quinolina uteis para inibir a farnesil-proteina-transferase
UA75055C2 (uk)	1999-11-30	2006-03-15	Пфайзер Продактс Інк.	Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
YU54202A (sh) *	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2000000266A (es) *	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
US6844357B2 (en) *	2000-05-01	2005-01-18	Pfizer Inc.	Substituted quinolin-2-one derivatives useful as antiproliferative agents
AR038957A1 (es)	2001-08-15	2005-02-02	Pharmacia Corp	Terapia de combinacion para el tratamiento del cancer

2003
- 2003-12-08 WO PCT/IB2003/005854 patent/WO2004056806A1/en not_active Ceased
- 2003-12-08 KR KR1020057011551A patent/KR100730267B1/ko not_active Expired - Fee Related
- 2003-12-08 OA OA1200500188A patent/OA12977A/en unknown
- 2003-12-08 NZ NZ540340A patent/NZ540340A/en unknown
- 2003-12-08 AU AU2003286321A patent/AU2003286321A1/en not_active Abandoned
- 2003-12-08 BR BR0317548-0A patent/BR0317548A/pt not_active IP Right Cessation
- 2003-12-08 CN CNA2003801096976A patent/CN1747950A/zh active Pending
- 2003-12-08 RS YUP-2005/0430A patent/RS20050430A/sr unknown
- 2003-12-08 JP JP2004561821A patent/JP3814285B2/ja not_active Expired - Fee Related
- 2003-12-08 CA CA002510850A patent/CA2510850A1/en not_active Abandoned
- 2003-12-08 MX MXPA05006676A patent/MXPA05006676A/es unknown
- 2003-12-08 DE DE60314013T patent/DE60314013T2/de not_active Expired - Fee Related
- 2003-12-08 SI SI200330833T patent/SI1585743T1/sl unknown
- 2003-12-08 EP EP03777064A patent/EP1585743B1/en not_active Expired - Lifetime
- 2003-12-08 AP AP2005003341A patent/AP2005003341A0/xx unknown
- 2003-12-08 EA EA200500811A patent/EA008501B1/ru not_active IP Right Cessation
- 2003-12-08 DK DK03777064T patent/DK1585743T3/da active
- 2003-12-08 PL PL377713A patent/PL377713A1/pl not_active Application Discontinuation
- 2003-12-08 AT AT03777064T patent/ATE362928T1/de not_active IP Right Cessation
- 2003-12-08 PT PT03777064T patent/PT1585743E/pt unknown
- 2003-12-08 HR HR20050559A patent/HRP20050559A2/hr not_active Application Discontinuation
- 2003-12-11 PE PE2003001269A patent/PE20041006A1/es not_active Application Discontinuation
- 2003-12-15 US US10/737,655 patent/US7053107B2/en not_active Expired - Fee Related
- 2003-12-17 UY UY28130A patent/UY28130A1/es not_active Application Discontinuation
- 2003-12-17 AR ARP030104683A patent/AR042510A1/es unknown
- 2003-12-17 PA PA20038592901A patent/PA8592901A1/es unknown
- 2003-12-18 NL NL1025073A patent/NL1025073C2/nl not_active IP Right Cessation
- 2003-12-18 GT GT200300294A patent/GT200300294A/es unknown
- 2003-12-18 TW TW092135955A patent/TW200424193A/zh unknown
2005
- 2005-05-23 IS IS7859A patent/IS7859A/is unknown
- 2005-05-27 ZA ZA200504339A patent/ZA200504339B/en unknown
- 2005-06-15 EC EC2005005858A patent/ECSP055858A/es unknown
- 2005-06-17 TN TNP2005000164A patent/TNSN05164A1/fr unknown
- 2005-06-17 CO CO05059483A patent/CO5580767A2/es not_active Application Discontinuation
- 2005-06-17 MA MA28348A patent/MA27570A1/fr unknown
- 2005-06-17 CR CR7882A patent/CR7882A/es not_active Application Discontinuation
- 2005-07-18 NO NO20053486A patent/NO20053486L/no not_active Application Discontinuation
- 2005-12-16 US US11/305,811 patent/US20060160858A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ECSP055858A (es)	2005-09-20
DE60314013D1 (de)	2007-07-05
PE20041006A1 (es)	2004-12-24
AR042510A1 (es)	2005-06-22
NZ540340A (en)	2007-07-27
RS20050430A (sr)	2007-08-03
EA200500811A1 (ru)	2005-12-29
IS7859A (is)	2005-05-23
JP2006515589A (ja)	2006-06-01
WO2004056806A1 (en)	2004-07-08
TNSN05164A1 (fr)	2007-05-14
CN1747950A (zh)	2006-03-15
JP3814285B2 (ja)	2006-08-23
ZA200504339B (en)	2006-07-26
DE60314013T2 (de)	2008-01-17
PT1585743E (pt)	2007-07-12
DK1585743T3 (da)	2007-09-17
US20040192735A1 (en)	2004-09-30
MXPA05006676A (es)	2005-08-16
US7053107B2 (en)	2006-05-30
TW200424193A (en)	2004-11-16
EP1585743B1 (en)	2007-05-23
UY28130A1 (es)	2004-07-30
MA27570A1 (fr)	2005-10-03
PA8592901A1 (es)	2005-02-04
EA008501B1 (ru)	2007-06-29
BR0317548A (pt)	2005-11-22
HRP20050559A2 (en)	2006-02-28
NO20053486L (no)	2005-07-18
KR100730267B1 (ko)	2007-06-20
CO5580767A2 (es)	2005-11-30
KR20050084439A (ko)	2005-08-26
EP1585743A1 (en)	2005-10-19
GT200300294A (es)	2004-07-27
PL377713A1 (pl)	2006-02-06
OA12977A (en)	2006-10-13
NL1025073A1 (nl)	2004-06-22
CA2510850A1 (en)	2004-07-08
ATE362928T1 (de)	2007-06-15
NL1025073C2 (nl)	2005-02-01
AU2003286321A1 (en)	2004-07-14
SI1585743T1 (sl)	2007-08-31
CR7882A (es)	2005-08-05
US20060160858A1 (en)	2006-07-20

Publication	Publication Date	Title
AP2005003341A0 (en)	2005-06-30	2-(1H-indazole-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatmentof ophthalmic diseases
AU2002310187A1 (en)	2002-12-09	Inhibitors of protein kinase for the treatment of disease
AP2005003283A0 (en)	2005-06-30	Indole derivatives useful for the treatment os diseases
IL164784A0 (en)	2005-12-18	Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
PL1651622T3 (pl)	2007-07-31	Sposób wytwarzania związków 2-(chinoksalin-5-ylosulfonyloamino)benzamidowych
PL371512A1 (pl)	2005-06-27	Związki indazolowe użyteczne jako inhibitory kinaz białkowych
AU2003285091A1 (en)	2004-06-07	Interferon antagonists useful for the treatment of interferon related diseases
SI1562589T1 (sl)	2009-06-30	Diaminotriazoli, koristni kot inhibitorji proteinkinaz
PT1411926E (pt)	2005-10-31	Inibidores de integrina para o tratamento de doencas oftalmicas
HUS2200036I1 (hu)	2022-08-28	Dihidroimidazolonok alkalmazása kutyák kezelésére
GB0329874D0 (en)	2004-01-28	Compounds useful for the treatment of diseases
AU2003256655A1 (en)	2004-02-16	Therapeutic compounds for treating dyslipidemic conditions
EP1562592A4 (en)	2009-01-21	HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE EYE
AU2003290059A1 (en)	2004-07-09	Use of cd137 antagonists for the treatment of tumors
PT1687023E (pt)	2013-01-23	Uso de histonas específicas para o tratamento de doenças parasitárias
GB2410744B (en)	2006-04-12	Kinase inhibitors for the treatment of disease
AU2003243214A1 (en)	2003-12-12	Salts of bis-arylsulfones for the treatment of cns disorders
HK1086001A (en)	2006-09-08	2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
ITMI20020583A0 (it)	2002-03-20	Procedimento per la funzionalizzazione di poliolefine
AU2002309243A1 (en)	2002-10-03	Heterocyclic compounds for therapeutic use
IL164377A0 (en)	2005-12-18	Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
AU2002343085A1 (en)	2003-06-10	Tnf-alpha inhibitors for the treatment of hepatic diseases
ME01496B (me)	2014-04-20	Primjena specifičnih histona za liječenje parazitnih bolesti
FR2848221B1 (fr)	2007-09-28	Procede de preparation d'heterocarpine recombinante
HK1074838A (en)	2005-11-25	Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases